BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Diabetic Macular Edema readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Diabetic Macular Edem
 a\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06962839-5344@assetmemo.bio
DTSTAMP:20261122T013012Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:BI 1815368: Phase 2 readout est. (NCT06962839)
DESCRIPTION:BI 1815368\, phase 2\, Diabetic Macular Edema.\nStudy: A Study 
 to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabe
 tic Macular Edema\nEstimated primary completion: 1 March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/bi-1815368#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06962839
URL:https://assetmemo.bio/drug/bi-1815368#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07734844-5078@assetmemo.bio
DTSTAMP:20261122T013012Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Tabirafusp tedromer: Phase 3 readout est. (NCT07734844)
DESCRIPTION:Tabirafusp tedromer\, phase 3\, Diabetic Macular Edema.\nStudy:
  A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compar
 ed to Aflibercept in Participants With DME - ALTO\nEstimated primary compl
 etion: 31 August 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tabirafusp-tedromer#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07734844
URL:https://assetmemo.bio/drug/tabirafusp-tedromer#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07936487-5061@assetmemo.bio
DTSTAMP:20261122T013012Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:RC28-E: Phase 3 readout est. (NCT07936487)
DESCRIPTION:RC28-E\, phase 3\, Diabetic Macular Edema.\nStudy: IIIb Trial f
 or RC28-E Injection in Participants With DME and wAMD\nEstimated primary c
 ompletion: 1 December 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/rc28-e#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07936487
URL:https://assetmemo.bio/drug/rc28-e#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
